Banner Top
Wednesday, September 28, 2022
Omega Diagnostics in recovery mode after ‘extremely challenging year’ including sale of Alva site

Healthcare firm Omega Diagnostics has told investors that it is in a stronger position following an “extremely challenging year” which led to the disposal of its Clackmannanshire facility.

Releasing full-year results, the group said the past 12 months had been dominated by a Covid-19 opportunity that “ultimately did not come to fruition” and which destabilised the whole business.

At the start of last month, Omega sold its CD4 testing business to the same Chinese-owned firm that bought its Clackmannanshire manufacturing facility earlier this year.

The group confirmed that it had completed the disposal of the loss-making CD4 operation to Accubio, a wholly-owned subsidiary of Zhejiang Orient Gene Biotech, for a total cash consideration of up to £6.1 million, before costs.

Banner Content